[开放获取]    药物超敏反应综合征诊治专家共识

doi:10.3760/cma.j.issn.0412-4030.2018.11.002

中华皮肤科杂志 ›› 2018, Vol. 51 ›› Issue (11): 787-790.doi: 10.3760/cma.j.issn.0412-4030.2018.11.002

[开放获取] 药物超敏反应综合征诊治专家共识

中国医师协会皮肤科医师分会变态反应性疾病专业委员会

中国医师协会皮肤科医师分会变态反应性疾病专业委员会

收稿日期:2018-07-11 修回日期:2018-08-27 发布日期:2018-10-31
通讯作者: 宋志强;郝飞 E-mail:zhiqiang.song@hotmail.com; haofei62@medmail.com.cn

Diagnosis and treatment of drug-induced hypersensitivity syndrome: an expert consensus statement

^{Committee on Allergic Diseases, China Dermatologist Association}

Committee on Allergic Diseases, China Dermatologist Association

Received:2018-07-11 Revised:2018-08-27 Published:2018-10-31
Contact: Song Zhi-Qiang;Hao Fei E-mail:zhiqiang.song@hotmail.com; haofei62@medmail.com.cn

摘要/Abstract

摘要： 药物超敏反应综合征（drug induced hyper?sensitivity syndrome，DIHS）又称伴嗜酸性粒细胞增多和系统症状的药物反应（drug reaction with eosinophilia and systemic symptoms，DRESS），是一种少见且可危及生命的药物不良反应，其特征是潜伏期较长，伴皮疹、血液系统异常和内脏损害［1?4］。本病的确切发病率不详（其中抗癫痫药物及磺胺类药物约为1/10 000），致死率可达10%［2，5?8］。临床上具有药物过敏和病毒感染的复合特征，呈现多样化表现，易误诊误治。为提高对本病的认识和处置水平，中国医师协会皮肤科医师分会变态反应性疾病专业委员会组织有关专家制定DIHS诊疗共识，供我国皮肤科及其他相关学科医师参考……

中国医师协会皮肤科医师分会变态反应性疾病专业委员会. [开放获取] 药物超敏反应综合征诊治专家共识[J]. 中华皮肤科杂志, 2018,51(11):787-790. doi:10.3760/cma.j.issn.0412-4030.2018.11.002

Committee on Allergic Diseases, China Dermatologist Association. Diagnosis and treatment of drug-induced hypersensitivity syndrome: an expert consensus statement[J]. Chinese Journal of Dermatology, 2018, 51(11): 787-790.doi:10.3760/cma.j.issn.0412-4030.2018.11.002

参考文献 36

［1］	Musette P, Janela B. New insights into drug reaction with eosinophilia and systemic symptoms pathophysiology［J］. Front Med （Lausanne）, 2017,4:179. doi: 10.3389/fmed.2017.00179.
［2］	Skowron F, Bensaid B, Balme B, et al. Drug reaction with eosinophilia and systemic symptoms （DRESS）: clinicopa⁃thological study of 45 cases［J］. J Eur Acad Dermatol Venereol, 2015,29（11）:2199⁃2205. doi: 10.1111/jdv.13212.
［3］	Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives［J］. J Am Acad Dermatol, 2013,68（5）:693.e1⁃e14. doi: 10.1016/j.jaad.2013.01.033.
［4］	Shiohara T, Kano Y, Takahashi R, et al. Drug⁃induced hyper⁃sensitivity syndrome: recent advances in the diagnosis, patho⁃genesis and management［J］. Chem Immunol Allergy, 2012,97:122⁃138. doi: 10.1159/000335624.
［5］	Wu X, Yang F, Chen S, et al. Clinical, viral and genetic characteristics of drug reaction with eosinophilia and systemic symptoms （DRESS） in Shanghai, China［J］. Acta Derm Venereol, 2018,98（4）:401⁃405. doi: 10.2340/00015555⁃2867.
［6］	Wang L, Mei XL. Drug reaction with eosinophilia and systemic symptoms: retrospective analysis of 104 cases over one decade［J］. Chin Med J （Engl）, 2017,130（8）:943⁃949. doi: 10.4103/0366⁃6999.204104.
［7］	Sasidharanpillai S, Sabitha S, Riyaz N, et al. Drug reaction with eosinophilia and systemic symptoms in children: a prospective study［J］. Pediatr Dermatol, 2016,33（2）:e162⁃e165. doi: 10.1111/pde.12803.
［8］	Ferner RE. Adverse drug reactions in dermatology［J］. Clin Exp Dermatol, 2015,40（2）:105⁃109. doi: 10.1111/ced. 12572.
［9］	Walsh SA, Creamer D. Drug reaction with eosinophilia and systemic symptoms （DRESS）: a clinical update and review of current thinking［J］. Clin Exp Dermatol, 2011,36（1）:6⁃11. doi: 10.1111/j.1365⁃2230.2010.03967.x.
［10］	Niu J, Jia Q, Ni Q, et al. Association of CD8+ T lymphocyte repertoire spreading with the severity of DRESS syndrome［J］. Sci Rep, 2015,5:9913. doi: 10.1038/srep09913.
［11］	Phillips EJ, Chung WH, Mockenhaupt M, et al. Drug hyper⁃sensitivity: pharmacogenetics and clinical syndromes［J］. J Allergy Clin Immunol, 2011,127（3 Suppl）:S60⁃S66. doi: 10.1016/ j.jaci.2010.11.046.
［12］	Ksouda K, Affes H, Mahfoudh N, et al. HLA⁃A*31:01 and carbamazepine⁃induced DRESS syndrom in a sample of North African population［J］. Seizure, 2017,53:42⁃46. doi: 10.1016/j.seizure.2017.10.018.
［13］	Ng CY, Yeh YT, Wang CW, et al. Impact of the HLA⁃B（*）58:01 allele and renal impairment on allopurinol⁃induced cutaneous adverse reactions［J］. J Invest Dermatol, 2016,136（7）:1373⁃1381. doi: 10.1016/j.jid.2016.02.808.
［14］	Yang F, Gu B, Zhang L, et al. HLA⁃B*13:01 is associated with salazosulfapyridine⁃induced drug rash with eosinophilia and systemic symptoms in Chinese Han population［J］. Pharmacogenomics, 2014,15（11）:1461⁃1469. doi: 10.2217/pgs. 14.69.
［15］	Zhang FR, Liu H, Irwanto A, et al. HLA⁃B*13:01 and the dapsone hypersensitivity syndrome［J］. N Engl J Med, 2013,369（17）:1620⁃1628. doi: 10.1056/NEJMoa1213096.
［16］	Gonçalo M, Coutinho I, Teixeira V, et al. HLA⁃B*58:01 is a risk factor for allopurinol⁃induced DRESS and Stevens⁃Johnson syndrome/toxic epidermal necrolysis in a Portuguese population［J］. Br J Dermatol, 2013,169（3）:660⁃665. doi: 10.1111/bjd. 12389.
［17］	Yue Z, Sun Y, Wang C, et al. Amino acid variants of HLA⁃DRB1 confer susceptibility to dapsone hypersensitivity syndrome in addition to HLA⁃B*13:01［J］. J Invest Dermatol, 2018,138（5）:1101⁃1106. doi: 10.1016/j.jid.2017.11.027.
［18］	Lin CY, Wang CW, Hui CR, et al. Delayed⁃type hypersensitivity reactions induced by proton pump inhibitors: a clinical and in vitro T⁃cell reactivity study［J］. Allergy, 2018,73（1）:221⁃229. doi: 10.1111/all.13235.
［19］	Avancini J, Maragno L, Santi CG, et al. Drug reaction with eosinophilia and systemic symptoms/drug⁃induced hypersensi⁃tivity syndrome: clinical features of 27 patients［J］. Clin Exp Dermatol, 2015,40（8）:851⁃859. doi: 10.1111/ced.12682.
［20］	Ishida T, Kano Y, Mizukawa Y, et al. The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome［J］. Allergy, 2014,69（6）:798⁃805. doi: 10.1111/all.12410.
［21］	Kano Y, Tohyama M, Aihara M, et al. Sequelae in 145 patients with drug⁃induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions （ASCAR）［J］. J Dermatol, 2015,42（3）:276⁃282. doi: 10.1111/1346⁃8138.12770.
［22］	Ang CC, Wang YS, Yoosuff EL, et al. Retrospective analysis of drug⁃induced hypersensitivity syndrome: a study of 27 patients［J］. J Am Acad Dermatol, 2010,63（2）:219⁃227. doi: 10.1016/j.jaad.2009.08.050.
［23］	Matsuda H, Saito K, Takayanagi Y, et al. Pustular⁃type drug⁃induced hypersensitivity syndrome/drug reaction with eosino⁃philia and systemic symptoms due to carbamazepine with systemic muscle involvement［J］. J Dermatol, 2013,40（2）:118⁃122. doi: 10.1111/1346⁃8138.12028.
［24］	Ardern⁃Jones MR. Atypical erythema multiforme is a prognostic indicator of severe hepatic dysfunction in Dress （Drug Reaction with Eosinophilia and Systemic Symptoms）［J］. Br J Dermatol, 2013,168（2）:234⁃235. doi: 10.1111/bjd.12191.
［25］	Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases［J］. Arch Dermatol, 2010,146（12）:1373⁃1379. doi: 10.1001/archdermatol. 2010.198.
［26］	Kardaun SH, Sidoroff A, Valeyrie⁃Allanore L, et al. Variability in the clinical pattern of cutaneous side⁃effects of drugs with systemic symptoms: does a DRESS syndrome really exist?［J］. Br J Dermatol, 2007,156（3）:609⁃611. doi: 10.1111/j.1365⁃2133. 2006.07704.x.
［27］	Skowron F, Bensaid B, Balme B, et al. Comparative histological analysis of drug⁃induced maculopapular exanthema and DRESS［J］. J Eur Acad Dermatol Venereol, 2016,30（12）:2085⁃2090. doi: 10.1111/jdv.13832.
［28］	Kim DH, Koh YI. Comparison of diagnostic criteria and determination of prognostic factors for drug reaction with eosinophilia and systemic symptoms syndrome［J］. Allergy Asthma Immunol Res, 2014,6（3）:216⁃221. doi: 10.4168/aair.2014.6.3. 216.
［29］	Shiohara T, Kano Y. Drug reaction with eosinophilia and systemic symptoms （DRESS）: incidence, pathogenesis and management［J］. Expert Opin Drug Saf, 2017,16（2）:139⁃147. doi: 10.1080/14740338.2017.1270940.
［30］	Chen YC, Chang CY, Cho YT, et al. Long⁃term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan［J］. J Am Acad Dermatol, 2013,68（3）:459⁃465. doi: 10.1016/j.jaad.2012.08.009.
［31］	Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part II. Management and therapeutics［J］. J Am Acad Dermatol, 2013,68（5）:709.e1⁃e9. doi: 10.1016/j.jaad.2013.01.032.
［32］	Funck⁃Brentano E, Duong TA, Bouvresse S, et al. Therapeutic management of DRESS: a retrospective study of 38 cases［J］. J Am Acad Dermatol, 2015,72（2）:246⁃252. doi: 10.1016/j.jaad. 2014.10.032.
［33］	Marcus N, Smuel K, Almog M, et al. Successful intravenous immunoglobulin treatment in pediatric severe DRESS syndrome［J］. J Allergy Clin Immunol Pract, 2018,6（4）:1238⁃1242. doi: 10.1016/j.jaip.2017.10.016.
［34］	朱伟芳, 李炎冬, 斯子翔, 等. 静脉注射丙种球蛋白和糖皮质激素治疗药物超敏综合征的疗效观察［J］. 中华急诊医学杂志, 2013,22（9）:1054⁃1056. doi: 10.3760/cma.j.issn.1671⁃0282. 2013.09.031.
［35］	陈玲玲, 路丹丹, 施辛, 等. 肿瘤坏死因子α拮抗剂治疗一例伴嗜酸性粒细胞增多和系统症状药疹的临床观察［J］.中华皮肤科杂志, 2013,46（9）:621⁃625. doi: 10.3760/cma.j.issn.0412⁃4030.2013.09.003.
［36］	王松, 尉晓冬, 许爱娥, 等. 药物超敏反应综合征后发生白癜风二例［J］. 中华皮肤科杂志, 2012,45（6）:447⁃448. doi: 10.3760/cma.j.issn.0412⁃4030.2012.06.027.

[开放获取] 药物超敏反应综合征诊治专家共识

Diagnosis and treatment of drug-induced hypersensitivity syndrome: an expert consensus statement

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 36

相关文章 0

Metrics

本文评价

推荐阅读 10